Ernexa Therapeutics Q1 Loss Per Share Worsens to $(6.95) Post-Split, Despite Narrower Net Loss
ERNA has more than doubled off its 52-week low of $3.183 on light trading volume (0.4× avg).
Summary
Ernexa Therapeutics Inc. reported a net loss of $(5.51) million for Q1 2026, an improvement from $(8.20) million in the prior year. However, the diluted loss per share of $(6.95) represents a significant deterioration when adjusted for the recent 1-for-25 reverse stock split, which became effective on May 4, 2026. On a split-adjusted basis, the prior year's loss per share was approximately $(2.31), indicating a substantial widening of per-share losses. This earnings report is critical for a micro-cap company already facing Nasdaq delisting threats and going concern doubts, as it highlights continued high cash burn relative to its ~$8.4 million market capitalization. Investors will closely watch the company's ability to manage its cash runway, progress its pipeline, and maintain Nasdaq compliance, especially given its existing dilutive capital programs.
At the time of this announcement, ERNA was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.4M. The 52-week trading range was $3.18 to $100.46. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.